Lifecore Biomedical Expands CDMO Role in Indomo’s Acne Treatment Development
Event summary
- Lifecore Biomedical signs second agreement with Indomo to manufacture drug batches for Phase 2 clinical trials of DT-001, a corticosteroid acne treatment.
- Indomo’s ClearPen™ device aims to enable at-home administration of DT-001, addressing accessibility issues in acne treatment.
- Lifecore expands beyond ophthalmic therapies, enhancing leadership in autoinjector technologies.
- Phase 2 clinical trials for DT-001 are planned for 2026.
The big picture
Lifecore Biomedical’s expanded role in Indomo’s acne treatment development highlights the growing trend of CDMOs diversifying into new therapeutic areas. The partnership underscores the strategic importance of autoinjector technologies in improving patient access to treatments. With the acne market being highly competitive, the success of DT-001 and ClearPen™ will depend on regulatory approval and clinical trial outcomes.
What we're watching
- Market Expansion
- How Lifecore’s shift beyond ophthalmic therapies will impact its market positioning and revenue streams.
- Regulatory Approval
- Whether Indomo’s ClearPen™ can secure FDA approval and enter the market successfully.
- Clinical Trial Success
- The pace at which Indomo advances DT-001 through Phase 2 clinical trials and potential market entry.
Related topics